Analysts cut target for Dis-Chem stock from ZAR 27.75 to ZAR 25.00

Published on 10/19/2026 at 02:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-half revenue rose 9.90 percent, while net margin fell to 1.60 percent. Dis-Chem stock faces results on October 30, 2026.

Sales growth meets margin pressure

Analysts lowered Dis-Chem's target from ZAR 27.75 to ZAR 25.00 on October 16, 2026.
Second-half revenue reached ZAR 21.55 billion in fiscal 2026 versus ZAR 19.61 billion in fiscal 2025.
Dis-Chem's next earnings release and presentation are scheduled for October 30, 2026.
Net income fell to ZAR 345.78 million in the second half of fiscal 2026.

Dis-Chem, ZAE000227831, Illustration mit AI erstellt.

Dis-Chem Pharmacies (ISIN ZAE000227831) became the subject of a lower valuation view on October 16, 2026, when its tracked analyst target fell from ZAR 27.75 to ZAR 25.00. Simply Wall St said the change reflected higher revenue expectations but lower forecast margins and a reduced future earnings multiple.

Three dates frame the debate

On May 29, 2026, the latest release listed by Investing.com showed revenue of ZAR 21.55 billion. On October 15, 2026, Simply Wall St compared second-half revenue of ZAR 21.55 billion in fiscal 2026 with ZAR 19.61 billion in fiscal 2025. The October 16 target revision was the latest of the three developments.

What do the margins mean?

The sales increase of 9.90 percent did not translate into stronger profitability. Net income declined to ZAR 345.78 million from ZAR 602.10 million, while net margin fell to 1.60 percent from 3.10 percent in the comparable second-half periods, according to Simply Wall St. The figures make cost control and operating leverage more important than sales growth alone.

For market context, Dis-Chem closed on the Johannesburg Stock Exchange at ZAc 2,721.00 on October 16, 2026. The same quoted market page places the 52-week range at ZAc 2,535.00 to ZAc 3,900.00, while the analyst update's ZAR 25.00 target uses a different unit convention from the JSE share quotation.

Results date adds the next test

MarketScreener lists October 30, 2026 for Dis-Chem's next earnings release and earnings presentation. That date gives investors a defined checkpoint for whether the revenue expansion can narrow the gap between demand growth and profit growth.

JSE valuation stays tied to execution

The immediate stock question is therefore operational rather than purely top-line. Dis-Chem has delivered higher second-half revenue, but the fall in net income and margin explains why the revised target emphasizes profitability, store expansion discipline and the future earnings multiple.